Second child free of cancer after treatment with Cellectis' UCART 19

9 May 2016

A second baby with acute lymphoblastic leukemia (ALL) who received the experimental UCART19 injection of French biotech company Cellectis (Euronext Paris: ALCLS) remains in remission six months after treatment, according to reports.

The 16-month-old girl was found to be recovering from the previously incurable disease at Great Ormond Street Hospital in London, providing further excitement about the potential of Cellectis’ allogeneic gene-edited chimeric antigen receptor T-cell (CAR-T) immunotherapy in fighting cancer.

News on the latest case comes as the first infant continues to be in remission almost a year after receiving the treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK